| Literature DB >> 31538434 |
Eu Seon Noh1, Hyun Ho Kim1, Hye Seon Kim1, Yea Seul Han1, Misun Yang1, So Yoon Ahn1, Se In Sung2, Yun Sil Chang1, Won Soon Park1.
Abstract
PURPOSE: Despite the increasing use of continuous renal replacement therapy (CRRT) in the neonatal intensive care unit (NICU), few studies have investigated its use in preterm infants. This study evaluated the prognosis of preterm infants after CRRT and identified risk factors of mortality after CRRT.Entities:
Keywords: Continuous renal replacement therapy; fluid overload; premature infants
Mesh:
Year: 2019 PMID: 31538434 PMCID: PMC6753340 DOI: 10.3349/ymj.2019.60.10.984
Source DB: PubMed Journal: Yonsei Med J ISSN: 0513-5796 Impact factor: 2.759
Baseline Characteristics of the Preterm Infants with CRRT
| Survivors (n=5) | Non-survivors (n=28) | Total (n=33) | ||
|---|---|---|---|---|
| Demographic data | ||||
| Gestational age (wk) | 33.6±5.0 (24.7–36.6) | 29.3±4.0 (22.7–36.9) | 30.0±4.4 (22.7–36.9) | 0.075 |
| Birth weight (g) | 2174±907 (720–3060) | 1359±763 (550–3710) | 1482±826 (550–3710) | 0.114 |
| Male | 4 (80) | 17 (60) | 21 (63) | 0.630 |
| Small for gestational age | 0 (0) | 5 (18) | 5 (15) | 0.452 |
| Outborn | 2 (40) | 17 (61) | 19 (58) | 0.360 |
| Antenatal steroid | 1 (20) | 19 (68) | 20 (60) | 0.066 |
| Apgar score at 1 min | 6.6±1.6 (4–8) | 4.4±2.4 (1–10) | 4.8±2.4 (1–10) | 0.044 |
| Apgar score at 5 min | 8.6±1.1 (2–10) | 6.5±2.1 (7–10) | 6.8±2.1 (2–10) | 0.028 |
| Predisposing morbidity | ||||
| Intraventricular hemorrhage grade III and IV | 1 (20) | 8 (29) | 9 (27) | 1.000 |
| Bronchopulmonary dysplasia, moderate to severe* | 2/5 (40) | 17/19 (89) | 19/24 (79) | 0.042 |
| Necrotizing enterocolitis stage ≥II | 1 (20) | 12 (43) | 13 (39) | 0.625 |
| Intestinal surgery | 1 (20) | 7 (25) | 8 (24) | 1.000 |
| Sepsis | 2 (40) | 19 (68) | 21 (63) | 0.328 |
| Cardiopulmonary instability at CRRT initiation | ||||
| Systolic blood pressure at CRRT initiation (mm Hg) | 73±26 (42–103) | 60±17 (34–111) | 62±19 (34–111) | 0.257 |
| Diastolic blood pressure at CRRT initiation (mm Hg) | 47±13 (33–63) | 31±16 (13–70) | 37±16 (13–70) | 0.103 |
| Inotropic support at CRRT initiation | 2 (40) | 26 (93) | 28 (85) | 0.017 |
| Hypotension episodes during the initiation of CRRT | 1 (20) | 10 (36) | 11 (33) | 0.492 |
| Mechanical ventilation during CRRT | 3 (60) | 28 (100) | 31 (94) | 0.019 |
| ECMO during CRRT | 0 (0) | 2 (7) | 2 (6) | 1.000 |
| Mean airway pressure at CRRT initiation (cmH2O) | 15±7 (8–22) | 17±8 (8–45) | 17±8 (8–45) | 0.729 |
| FiO2 at CRRT initiation | 0.56±0.37 (0.21–1.0) | 0.63±0.25 (0.21–1.0) | 0.63±0.26 (0.21–1.0) | 0.681 |
| Persistent PDA at CRRT initiation | 0 (0) | 7 (25) | 7 (21) | 0.559 |
| CRRT data | ||||
| Postnatal age (day) | 44±63 (4–155) | 58±51 (2–183) | 56±52 (2–183) | 0.609 |
| Corrected age (wk) | 40.0±4.0 (36.5–46.8) | 37.6±5.9 (29.0–54.0) | 38.0±5.7 (29.0–46.8) | 0.303 |
| Duration of CRRT (day) | 15.6±26.5 (3–63) | 8.3±7.6 (1–38) | 9.4±12.0 (1–63) | 0.463 |
| Body weight at CRRT initiation (g) | 3258±580 (2640–4180) | 2984±1443 (1250–8400) | 3025±1345 (1250–8400) | 0.314 |
| Body weight at the end of CRRT | 3032±597 (2480–3910) | 2582±1379 (1390–7410) | 2659±1282 (1390–7410) | 0.162 |
| Fluid overload at CRRT initiation (%) | 4.0±7.3 | 16.8±12.6 | 14.8±12.7 | 0.031 |
| Fluid overload of >;10% at CRRT initiation | 1 (20) | 23 (82) | 24 (72.7) | 0.013 |
| Fluid reduction by CRRT (%) | −6.6±11.9 | −7.3±16.2 | −7.2±15.4 | 0.758 |
| Urine output at CRRT initiation [mL/(kg·hr)] | 0.88±1.01 | 0.94±1.58 | 0.93±1.52 | 0.643 |
| eGFR at CRRT initiation [mL/(min·1.73 m2)] | 12.5±14.1 | 23.4±20.2 | 20.6±19.4 | 0.173 |
| Blood flow rate [mL/(kg·min)] | 8.5±1.7 | 9.7±3.1 | 9.5±2.9 | 0.335 |
| Mean effluent volume [mL/(h·1.73 m2)] | 1837±243 | 2038±418 | 2006±393 | 0.511 |
| Hemofilter life span (h) | 56.3±27.3 | 49.2±38.1 | 50.2±36.4 | 0.419 |
| BUN level at CRRT initiation (mg/dL) | 63.2±34.4 | 62.4±41.8 | 62.5±40.3 | 0.960 |
| Δ BUN (at discontinuation−initiation of CRRT) (mg/dL) | −49.3±32.3 | −48.0±40.1 | −48.3±39.0 | 0.897 |
| Serum creatinine at initiation (mg/dL) | 3.30±2.31 | 1.64±1.44 | 1.87±1.57 | 0.116 |
| Δ Serum creatinine (at discontinuation−initiation of CRRT) (mg/dL) | −2.8±2.1 | −1.2±1.4 | −1.5±1.6 | 0.071 |
| Serum albumin level at initiation (g/dL) | 2.81±0.56 | 2.43±0.82 | 2.58±0.72 | 0.129 |
| Δ Serum albumin (at discontinuation−initiation of CRRT) (g/dL) | 0.34±0.74 | 0.18±0.84 | 0.23±0.78 | 0.758 |
CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; FiO2, fractional inspiration of oxygen; PDA, patent ductus arteriosus; eGFR, estimated glomerular filtration rate; BUN, blood urea nitrogen.
Values are presented as a mean±standard deviation (range) or n (%) unless otherwise noticed.
*Among survivors at 36 weeks' postmenstrual age.
Indications for CRRT in Preterm Infants
| Survivors (n=5) | Non-survivors (n=28) | Total (n=33) | |
|---|---|---|---|
| Sepsis | 1 (20) | 9 (32) | 10 (30) |
| Necrotizing enterocolitis | 0 | 9 (32) | 9 (27) |
| Inborn error of metabolism | 1 (20) | 2 (7) | 3 (9) |
| OTC deficiency | 0 | 1 (4) | 1 (3) |
| Citrullinemia | 0 | 1 (4) | 1 (3) |
| LCHAD deficiency | 1 (20) | 0 | 1 (3) |
| Fetal hydrops | 0 | 3 (11) | 3 (9) |
| Congenital heart disease | 0 | 3 (11) | 3 (9) |
| Pulmonary atresia with intact ventricular septum | 0 | 1 (4) | 1 (3) |
| Severe mitral valve regurgitation | 0 | 1 (4) | 1 (3) |
| Coarctation of aorta | 0 | 1 (4) | 1 (3) |
| Multicystic dysplastic kidney | 2 (40) | 0 | 2 (6) |
| Congenital diaphragmatic hernia | 0 | 1 (4) | 1 (3) |
| Acute kidney injury due to unknown reason | 0 | 1 (4) | 1 (3) |
| Renal failure due to antenatal medication* | 1 (20) | 0 | 1 (3) |
CRRT, continuous renal replacement therapy; OTC, ornithine transcarbamylase; LCHAD, long-chain 3-hydroxyacyl-CoA dehydrogenase.
Values are presented as n (%).
*Angiotensin-converting enzyme inhibitor.
Univariable Analysis of In-Hospital Mortality in Preterm Infants with CRRT
| OR | 95% CI | ||
|---|---|---|---|
| Demographic data | |||
| Gestational age | |||
| 35–36 weeks (reference) | |||
| 28–34 weeks | 12 | 0.90–160.40 | 0.060 |
| 22–27 weeks | 13 | 0.98–172.95 | 0.052 |
| Birth weight | |||
| ≥2 kg (reference) | |||
| 1.0–1.9 kg | 7.5 | 0.89–63.35 | 0.120 |
| <1.0 kg | 10.5 | 0.84–130.66 | 0.068 |
| Male | 0.39 | 0.06–2.70 | 0.422 |
| Antenatal steroid | 8.44 | 0.82–86.83 | 0.073 |
| Small for gestational age | 0.58 | 0.09–3.65 | 0.626 |
| Outborn | 2.7 | 0.53–13.85 | 0.318 |
| Apgar score at 1 min ≤5 | 8.44 | 0.82–86.83 | 0.073 |
| Apgar score at 5 min <7 | 8.44 | 0.82–86.83 | 0.073 |
| Predisposing morbidity | |||
| Intraventricular hemorrhage grade III or IV | 1.6 | 0.22–11.39 | 0.694 |
| Bronchopulmonary dysplasia, moderate to severe | 12.75 | 1.26–128.77 | 0.031 |
| Necrotizing enterocolitis stage ≥II | 3 | 0.43–20.94 | 0.352 |
| Intestinal surgery prior to CRRT | 1.33 | 0.18–9.60 | 0.811 |
| Sepsis | 3.17 | 0.61–16.36 | 0.248 |
| Cardiopulmonary instability prior to or during CRRT | |||
| Mean blood pressure at CRRT initiation | |||
| 4th quartile (reference) | |||
| 1st quartile | 3.2 | 0.35–29.52 | 0.392 |
| 2nd quartile | 2.4 | 0.25–22.70 | 0.522 |
| Inotropic support at CRRT initiation | 19.5 | 1.96–193.65 | 0.011 |
| Mean airway pressure at CRRT initiation (per 5 cmH2O) | 1.04 | 0.89–1.22 | 0.646 |
| FiO2 at CRRT initiation, per 0.1 increase | 2.94 | 0.06–150.88 | 0.651 |
| CRRT data | |||
| Postnatal age ≤30 days | 0.43 | 0.08–2.20 | 0.396 |
| Corrected age ≤37 weeks | 2 | 0.39–10.18 | 0.484 |
| Duration of CRRT (per day) | 0.96 | 0.91–1.02 | 0.253 |
| Body weight at CRRT initiation | |||
| 2.7–3.3 kg (reference) | |||
| <2.7 kg | 5.6 | 0.63–49.92 | 0.196 |
| >3.3 kg | 1.8 | 0.27–11.83 | 0.608 |
| Fluid reduction by CRRT (per 1% increase) | 1 | 0.94–1.05 | 0.926 |
| Fluid overload at CRRT initiation (per 1% increase) | 1.17 | 1.03–1.33 | 0.042 |
| Fluid overload >10% at CRRT initiation | 18.4 | 1.68–201.86 | 0.017 |
| Anuria at the end of CRRT | 1.89 | 0.27–13.39 | 0.591 |
CRRT, continuous renal replacement therapy; OR, odds ratio; CI, confidence interval; FiO2, fractional inspiration of oxygen.